Osaic Holdings’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Osaic Holdings’s Portfolio KTTAW Stock Details KTTAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,000	Closed	-$150	–	8095
2026 Q1	$150	Buy	+15,000	New	+$183	﹤0.01%	7592

Other funds holding KTTAW

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Osaic Holdings's KTTAW Position: Q2 2026 in Review

Osaic Holdings sold out of Pasithea Therapeutics Warrants (KTTAW) in Q2 2026, closing a stake of 15,000 shares — an estimated $150 sold.

Osaic Holdings first reported a position in KTTAW in Q1 2026 and held it in 1 quarter. The position peaked at $150 in Q1 2026. 6 funds tracked by Wall St. Rank hold KTTAW as of Q2 2026.

Osaic Holdings reported no remaining Pasithea Therapeutics Warrants position as of Q2 2026 after selling out during the quarter.
Osaic Holdings sold 15,000 Pasithea Therapeutics Warrants shares in Q2 2026, an estimated $150.
Osaic Holdings first reported a position in Pasithea Therapeutics Warrants in Q1 2026 and held it in 1 quarter.
Osaic Holdings's Pasithea Therapeutics Warrants position peaked at $150 in Q1 2026.
6 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.